Pioneering access for patients with chronic conditions during the COVID-19 pandemic
Jun 16, 2020
The COVID-19 pandemic has undoubtedly put the lives of millions of people worldwide on hold. For people living with chronic conditions, they may have added concerns around whether they will continue to be able to access the medicine they need to effectively manage their disease. As pharmaceutical companies who serve these patients, we hear the concerns and are quickly adapting to our new normal to meet the increasing demands from patients and governments.
Over 500 million patients worldwide rely on Sandoz to consistently produce and deliver the generic and biosimilar medicines they need. While a large part of the Sandoz workforce continues to work hard remotely to understand and anticipate these increasing demands – some things, such as producing high-quality medicines, just can’t be done from home! We are so proud of our colleagues, who in the midst of these challenging times, continue to operate our manufacturing plants and produce much needed medicines for patients worldwide.
These include associates at our production facilities in Austria, where many of our biosimilars are produced, are working tirelessly to make sure this happens. Despite the current challenges, they leave their homes every day and travel to work at Schaftenau, with the needs of our patients front and centre in their thoughts.
Watch the video below to learn more about how Sandoz employees are making a difference to millions of lives worldwide during these challenging times.